Top-News
Biotechnologie USA

Regulus Therapeutics Inc Aktie

Aktie
WKN:  A3DNZ4 ISIN:  US75915K3095 US-Symbol:  RGLS
7,84 $
-0,01 $
-0,13%
6,9021 € 15:38:33 Uhr
Depot/Watchlist
Aktienanzahl *
66,24 Mio.
Marktkapitalisierung *
466,58 Mio. €
Streubesitz
11,13%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 25.04.2025

Regulus Therapeutics Inc News

01.05.25 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, SWTX on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, SWTX on Behalf of Shareholders PR Newswire
30.04.25 - PR Newswire
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS PR Newswire
30.04.25 - PR Newswire
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG PR Newswire
02.04.25 - PR Newswire
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit PR Newswire
27.03.25 - PR Newswire
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal ...
13.03.25 - PR Newswire
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates PR Newswire
04.03.25 - PR Newswire
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference PR Newswire
04.02.25 - PR Newswire
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference PR Newswire
29.01.25 - PR Newswire
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) ...
26.11.24 - PR Newswire
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences PR Newswire
07.11.24 - PR Newswire
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates PR Newswire
08.10.24 - PR Newswire
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients ...
28.08.24 - PR Newswire
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire
08.08.24 - PR Newswire
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates PR Newswire
06.08.24 - PR Newswire
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference PR Newswire
09.07.24 - PR Newswire
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire
24.06.24 - PR Newswire
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the ...
04.06.24 - PR Newswire
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire
16.05.24 - PR Newswire
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire
09.05.24 - PR Newswire
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates PR Newswire

Newssuche

Videos

newspaper
30.04.25 +5,62%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »